BioWorld Asia

Nov. 1, 2006

CAT's Humira Royalty Sold By AstraZeneca For $700M

LONDON - AstraZeneca plc, the new owner of Cambridge Antibody Technology Group (CAT) Ltd., sold the royalty rights to the antibody company's one marketed product, Humira, for $700 million. (BioWorld International) Read More

Hold On Paion's Desmoteplase Lifted; Phase III Back On Track

Schizophrenia Gene Study Reveals Influence On Brain

Ethics Questions Delay Europe's Decision On Advanced Therapies

Cytheris' €24M Series B Round Should Fuel Company Into 2009

No Abstract Read More

Innate Planning For IPO, Seeking €25M To €36M

No Abstract Read More

LibraGen Enters Research Deal With Sanofi-Aventis

Renovo Reports Positive Data In Third Juvista Phase II Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 23, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...